Shares in Johnson & Johnson (NYSE:JNJ) fell yesterday after the healthcare giant topped Wall Street’s expectations for fourth-quarter results but missed analysts’ forecast for the full-year.
Despite taking a $13.6 billion hit to its unremitted foreign earnings thanks to new efforts to reform the U.S. tax system, the company said it is pleased with the legislation and that it plans to “invest in innovation at higher levels to help address the most challenging unmet medical needs facing health care today.”
Get the full story at our sister site, Drug Delivery Business News.
The post Pharma revenue drives Johnson & Johnson’s Q4 beat appeared first on MassDevice.
from MassDevice http://ift.tt/2E8tvJT
Cap comentari:
Publica un comentari a l'entrada